Answer
In adults receiving Besponsa (inotuzumab ozogamicin) for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, nausea was reported in 31% and vomiting in 15%; both are very common (affecting at least 1 in 10 patients).
Sources for this answer
- BESPONSA 1 mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.8 Undesirable effects · Version 12Document updated
Sources checked